Recent reports suggest that specific inhibitors that target H3K79 methylation and DOT1L are currently under development for the treatment of various types of cancer.[85] Given the formidable challenge of drug resistance in BC, researchers have continuously explored novel therapeutic targets and strategies. This evidence concerns the gene DOT1L and cancer.